ArticleAdvanced healthcare materials2026
Smart Immunomodulating Nanocomposites Enabling on-Demand Solid Tumor Treatment With Quasi-Real-Time Response Monitoring.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Recent advances in cancer immunotherapy face challenges such as limited efficacy in solid tumors, adverse effects, and prohibitive costs. This study addresses these challenges by developing a theranostic magnetic nanocomposite (mNC) system for on-demand delivery of small-molecule immunomodulating drugs (smIDs) to solid tumors. This system enables externally triggered drug release under alternating magnetic fields (AMFs) and simultaneous MRI monitoring. Functionalization with a granzyme B (GzmB)-responsive fluorescent probe allows real-time assessment of immune activation, focusing on NK cells and CTLs. In vitro and ex vivo validation demonstrated effective mobilization of innate and adaptive immune responses, resulting in approximately 60% tumor cell viability reduction correlating with GzmB activity and increased cytokine release. Validation further demonstrated the ability of the system to report tumor accumulation (via MRI) and immune cell activation (optical imaging). This platform offers precise spatio-temporal control of immunotherapy delivery combined with noninvasive imaging and immune response monitoring, representing a promising strategy for enhancing the specificity and efficacy of cancer immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.